Please login to the form below

Innovative approaches in the treatment of multiple sclerosis

Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.

Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. It is estimated that 2,500,000 people across the world suffer from MS. The disease impacts everyone differently, with the symptoms ranging from fatigue and vision problems to mental health issues and mobility problems, along with issues with speech and swallowing, and loss of bladder function (to name a few). Sadly, the age of onset is typically 20-40 years and MS is the leading cause of nontraumatic neurologic disability in young people.

The pathogenesis of MS consists of two key components: focal inflammatory demyelination, and neurodegeneration. Nerve function is dependent on the ability of electrical signals to flow through the wire-like axons of neurons, which are wrapped in and insulated by myelin sheaths. In the central nervous system (CNS, which includes the brain, optic nerves and spinal cord), myelin extends from octopus-like arms of oligodendrocytes. This myelination supports neuronal signal conductance and the survival of the neurons themselves.

However, in MS, lymphocytes mount an auto-immune attack on myelin, leading to damage of the myelin sheath. The demyelinated neurons can then no longer function properly and begin to atrophy and degenerate, causing the symptoms of MS.2 As damage can occur anywhere in the CNS, symptoms are highly varied.

THE TWO TYPES OF MS

There are two main clinical presentations of MS – Relapsing Refractory MS (RRMS) and Progressive MS (PMS).

In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and longer-lasting as the disease progresses. However, PMS is characterised by a progressive worsening of symptoms between flareups, without remission. Pathophysiologically, the disease courses of both types overlap. As a result, patients can transition between the types of MS, making monitoring and treating the disease more challenging.

For example, PMS is characterised by focal inflammatory lesions (an area of damage or scaring in the CNS, also referred to as plaques) in the early stages only, with more diffuse damage becoming common later on. Focal inflammatory lesions are also a feature throughout RRMS, and it is also possible for RRMS patients to show progressive symptoms in the later stages of the disease.

DOWNLOAD THE FULL ARTICLE

24th January 2019

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Three strategies for managing loss of exclusivity successfully
Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health